Citations

Clear

2853 citation(s) found for "Park, SH".

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
Sen, Mitali , Ruan, Gordon J , Reynolds, Samuel , Ali, Haadi , Morlote, Diana M. , Koster, Matthew J , Abeykoon, Jithma P , Salama, Hind , Ahmed, Asra Z , Go, Ronald S , Goyal, Guarav

Mayo Clinic

British Journal of Haematology | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70939 | PMID 43014348 Get It

Summary Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003 to 2025 at five international referral centres. Median age was 48 years and 64.8% were female. Multisystem disease occurred in 87 patients (53.7%), commonly involving skin/subcutaneous tissue (49.4%), lymph nodes (39.5%) and bones (34%). Molecular testing was available for 102 patients; 40 (39.2%) were mitogen‐activated protein kinase/rat sarcoma virus oncogene homolog signaling pathway (MAPK/RAS)‐altered, commonly with kirsten rat sarcoma viral oncogene homolog ( KRAS ) or mitogen‐activated protein kinase 1 ( MAP2K/MEK ) alterations. MAPK/RAS alterations were associated with multisystem disease ( p = 0.0034). Autoimmune disease (AID) was documented in 29 patients (17.9%), usually preceding RDD, and 45/95 patients (47.4%) with available autoantibody status had at least one positive autoantibody. Among 153 patients with response data, objective response occurred in 94 (61.4%). Response distribution differed by disease extent; single‐system disease was associated with more complete responses and less progression than multisystem disease. At a median follow‐up of 2.49 years, eight deaths occurred; 5‐year overall survival was 93.4%. AID and autoantibody positivity were not associated with response or overall survival. These findings support disease extent and molecular status as clinically relevant dimensions of RDD assessment, while autoimmune and serological abnormalities should be interpreted in clinical context.
Impactful Research in Microtia and Auricular Reconstruction
Gharavi, Aidin , Park, Rachel M, Garcia, Jose Castro

Mayo Clinic

Annals of Plastic Surgery | October 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sap.0000000000004869 | PMID 42932237 Get It

Introduction: Microtia is a complex congenital auricular deformity, with research spanning operative technique, epidemiology/genetics, biomaterials, and complications. Despite this breadth, there is limited work characterizing which studies have been most influential in shaping the field. This study aimed to identify and analyze the top 100 most-cited articles on microtia using a bibliometric approach. Methods: A comprehensive search using the Web of Science (WoS) was conducted to identify studies on microtia, and the top 100 articles were selected by citation count. Bibliometric data, study type (clinical, review, and basic science), clinical focus category, materials discussed, and sample sizes for clinical studies were extracted. Spearman correlation tests and Kruskal-Wallis tests were used to analyze citation patterns. Results: The top 100 microtia studies, published between 1957 and 2022, accumulated 12,692 total citations, with a mean of 127±84 citations per article, and were published across 49 journals. Clinical studies predominated (n=58), followed by reviews (n=28) and basic science studies (n=14). Publication year significantly differed by article type ( P =0.02), with basic science studies tending to be more recent. Newer publication year was associated with higher citations per year ( P <0.001) but fewer total citations overall ( P =0.002). Among clinical studies, technique-focused papers were most common (n=27) and were largely centered on autologous costal cartilage reconstruction (n=25). Clinical studies examining alternative materials were less represented but tended to be more recent publications. Conclusion: These findings suggest that the most-cited microtia literature has primarily included landmark clinical technique papers, but newer, rapidly cited work increasingly reflects emerging biomaterials and tissue engineering.
From Paper to Pixels: The Final Print Issue of Clinical Chemistry
Park, Jason Y

Mayo Clinic

Clinical Chemistry | October 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/clinchem/hvag159 | PMID 43021710 Get It

Endoscopic Decompression for Lateral Recess Stenosis Due to Vertebral Compression Fracture
Yasin Yavuz, Ahmed , Zarra, Francisco , Kumar, Harendra , Bozkurt, Ismail , Senturk, Salim

Mayo Clinic

Clinical Spine Surgery | October 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/bsd.0000000000002180 | PMID 42886585 Get It

Study Design: Case presentation. Objective: The interlaminar endoscopic lateral recess decompression (IE-LRD) represents a novel surgical alternative to consider in carefully selected cases, particularly when patients do not respond to conservative treatment. Background: Lumbar spinal stenosis (LSS) constitutes one of the most prevalent spinal conditions in the elderly population around the world. A myriad of causes have been elucidated, and although infrequent, vertebral compression fractures (VCF) may also cause LSS. Conservative treatment might be the first option; however, patients often require surgery. Methods: A 76-year-old woman with a medical history of dementia consulted for radicular pain in her left leg during the past 6 months, without any favorable response to conservative treatment. Neurological examination revealed a positive straight leg raising test on the left. A spine MRI revealed a VCF in L5, linked with spondylolisthesis (grade I) at L5–S1. An IE-LRD was planned, as the patient did not consent to a classical open surgery. The incision was placed over the inferior medial edge of the left L4 lamina. Following sequential dilatators, the working channel was located on the inferomedial edge of the left L4 lamina. Lateral fluoroscopy (LF) guided the entire procedure. During the procedure, laminotomy was extended cranially and caudally to ensure sufficient vertebral decompression. Results: After surgery, the patient was mobilized in the first 6 hours and discharged in the next 24 hours. Her lower back pain score improved significantly to 2–3, while her leg VAS pain improved to 0–1. After a follow-up for 18 months, the patient did not manifest complications or recurrences, and no additional treatment was carried out. Conclusion: (1) IE-LRD might be a useful and safe surgical procedure for the surgical management of LSS caused by VCF. (2) Consider this surgical alternative for elderly patients without a previous response to conservative medical treatment.
How to Interpret Needle EMG Study
Pucci, Gabriela F , Minkis, Jonathan , Pinto, Marcus V , Zelikovich, Aaron S

Mayo Clinic

Neurology Education | October 15, 2026 | Volume: 5 | Issue: 4 | Pages: No page available

10.1212/ne9.0000000000200370 | PMID 42893281 Get It

Shark Bites in Florida Are Underreported: A Multi-Dataset Analysis
Sheele, Johnathan M , Park, Jaeyoung , Thurmond, Samuel W , Spelsberg, Sarah S , Simon, Leslie V. , Bachista, Kerry

Mayo Clinic

Wilderness & Environmental Medicine | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10806032261491282 | PMID 42867903 Get It

Introduction There is uncertainty about the number of shark bites on humans in Florida (FL). Methods The International Shark Attack File (ISAF) and Global Shark Attack File (GSAF) databases (2016–2024) were compared with the non-inpatient FL Ambulatory and Emergency Department Patient Data database (AHCA) (2018–2023) and the National Emergency Medical Services (EMS) Information System (NEMSIS) (2016–2024). Results Between 2016–2024 there were 244 FL shark encounters reported in ISAF (mean 27.1 per year), 214 in GSAF (mean 23.8 per year), and 293 in a merged ISAF and GSAF (mean 32.6 per year). Between 2020–2023, there were 373 FL shark encounters reported in AHCA (mean 62.2 per year) compared with 114 encounters reported in NEMSIS (mean 22.8 per year) for 2020–2024. The rate ratio for AHCA FL shark encounters compared to the merged ISAF and GSAF was 1.91 (95% CI 1.64–2.23); p < .001. The percentage of shark encounters in Volusia County, FL, compared with all of FL shark encounters showed no significant differences between the ISAF and GSAF (40.2% and 33.6%, respectively) ( p = .16) and between the AHCA and NEMSIS (7.2% and 7.5%, respectively) ( p = 1.0). However, when comparing either ISAF or GSAF with either AHCA or NEMSIS, there were significant differences ( p < .001 for all). Discussion The AHCA dataset identified about twice as many shark bites as either the ISAF or GSAF. Many FL shark encounters did not require EMS or admission to the hospital. The discrepancy in the number of shark encounters attributed to Volusia County, FL, varied based on the dataset being examined.
Longitudinal Surgical Modeling of Early Glioblastoma Recurrence Reveals Emergence of Margin-Associated Neural Programs
Malla, Adarsha P. , Flick, Matthew , Fang, Jennifer R. , Fan, Xiaoxuan , Chen, Chixiang , Beniwal, Angad , Sereduk, Chris , Drexler, Richard , Poulopoulos, Alexandros , Monje, Michelle , Anastasiadis, Pavlos , Tran, Nhan L. , Winkles, Jeffrey A.

Mayo Clinic

Cancer Research | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/0008-5472.can-25-5176 | PMID 42831833 Get It

Abstract Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron–glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurologic function and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) platform. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multiregional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of postsurgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary versus postsurgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron–glioma signaling. Overall, the MSIS approach offers opportunities to model the standard of care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology. Significance: A clinically derived stereotactic resection platform models surgical resection in glioblastoma, enabling longitudinal tissue sampling and revealing conserved early-recurrence neuron-glioma programs in patient-derived models.
Dual Immunotherapy in Aggressive Lymphoma (DIAL) study, a randomized phase 2 trial of Varlilumab in combination with Nivolumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Sassi, Rafael Hennemann , Geyer, Susan, Kline, Justin, Lazaryan, Aleksandr , Bartlett, Nancy, Karmali, Reem , Geethakumari, Praveen, Awan, Farrukh, Reeder, Craig B. , Hernandez-Ilizaliturri, Francisco, Diefenbach, Catherine , Lansigan, Frederick , Shune, Leyla, Postovalova, Ekaterina, Bagaev, Alexander , Fowler, Nathan, Costello, Brian, Shapiro, Geoffrey, Ansell, Stephen M. , Villasboas, José C. , Karmali, Reem

Mayo Clinic

No container title available | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10845316/v1 Get It

Abstract Varlilumab is a monoclonal antibody with agonistic activity on CD27. The efficacy of single-agent PD-1 inhibitors on aggressive B-cell non-Hodkin lymphoma is limited. Preclinical and phase 1 data suggest that Varlilumab is safe and may have synergistic activity with PD-1 inhibitors. In the DIAL study, we explored whether dual immunomodulatory therapy with Varlilumab and Nivolumab in patients with relapsed/refractory aggressive B-NHL was safe and effective. We conducted a randomized phase II clinical trial on adult patients with relapsed/refractory aggressive B-NHL. Patients were randomized to receive Nivolumab monotherapy in the control group and Varlilumab combined with Nivolumab in the experimental group. Crossover to the experimental group was allowed upon progression in the control group. The primary endpoint was the overall response rate based on the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC). 54 patients underwent randomization, and 51 received assigned intervention and were included in the intention-to-treat analysis. Objective response was observed in 6 out of 51 patients (ORR 12%). There were 4 responders (ORR 16%) in the Nivolumab group and 2 responders (ORR 7.6%) in the Nivolumab and Varlilumab combination group (p = 0.3). None of the 7 patients that crossed over to the experimental group responded to the addition of Varlilumab. The ORR of patients who were previously exposed to CAR-T cell therapy was 13% (5 out of 39) compared to 8.3% (1 out of 12) in the unexposed patients (p > 0.99). The rate of treatment emergent adverse events was similar between groups, and there was no fatal TEAE in the study. The addition of Varlilumab to Nivolumb did not improve outcomes in patients with aggressive B-NHL. Even though this trial was not designed to evaluate immunotherapy as a rescue therapy after CAR-T failure, most patients (76%) had previously received CAR-T therapy, and their outcomes were equally poor.
Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer
Zhou, Qin, Dibbs, Anna, Yin, Ping, Pavelko, Kevin D. , Dong, Haidong , Luo, Kuntian, Tu, Xinyi , Lucien, Fabrice , Park, Sean S. , Grams, Michael P. , Xu‐Welliver, Meng , Callaghan, Cameron , Lou, Zhenkun, Mutter, Robert W., Han, Yiqun , Zhu, Shouhai , Yin, Ping, Lou, Zhenkun , Mutter, Robert W. , Lucien-Matteoni, Fabrice

Mayo Clinic

Frontiers in Immunology | September 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1929236 | PMID 42827904 Get It

Introduction Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear. Methods SYK expression and clinical relevance were assessed across multiple breast cancer cohorts, including radiotherapy-treated datasets. Integrated transcriptomic analyses were used to characterize SYK-associated immune states. The functional effects of pharmacologic SYK inhibition were evaluated using in vitro assays and an immunocompetent bilateral 4T1 tumor model in female BALB/c mice treated with radiotherapy and PD-1 blockade. Treatment-associated immune remodeling was assessed by flow cytometry and transcriptomic profiling. Results Across multiple cohorts, elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation. Pharmacologic SYK inhibition enhanced tumor responses to radiotherapy and PD-1 blockade at both irradiated and distant tumor sites. These effects were accompanied by coordinated remodeling of the tumor immune microenvironment, including suppression of neutrophil-associated signatures and reductions in immunosuppressive myeloid populations, including M2-like macrophages and myeloid-derived suppressor cells. Discussion Pharmacologic SYK inhibition enhances responses to radiotherapy and PD-1 blockade in preclinical TNBC models and is accompanied by remodeling of the immunosuppressive myeloid compartment. These findings support further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade.